Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5083636 | 0.76 | MAOB (0.42) | RELAALDH1A1TSHRTP53MEN1 | |
| SCHEMBL1509680 | 0.76 | MAOB (0.42) | RELAALDH1A1TSHRTP53MEN1 | |
| SCHEMBL4340782 | 0.76 | MAOB (0.36) | ALDH1A1IDO1TSHRTP53MAOB | |
| Ammonia Solution, Strong SCHEMBL9795266 | 0.75 | ALDH1A1 (0.43) | ALDH1A1IDO1TSHRMEN1KMT2A | |
| SCHEMBL4333668 | 0.73 | ALDH1A1 (0.38) | RELAALDH1A1IDO1TSHRMAOB | |
| SCHEMBL10767206 | 0.71 | ALDH1A1 (0.36) | RELAALDH1A1TSHRMAOBCYP2A6 | |
| SCHEMBL15525731 | 0.71 | ALDH1A1 (0.36) | RELAALDH1A1TSHRMAOBCYP2A6 | |
| SCHEMBL10767209 | 0.71 | ALDH1A1 (0.36) | RELAALDH1A1TSHRMAOBCYP2A6 | |
| SCHEMBL1178413 | 0.69 | ALDH1A1 (0.43) | ALDH1A1IDO1TSHRMEN1KMT2A | |
| SCHEMBL5701503 | 0.69 | ALDH1A1 (0.43) | ALDH1A1TSHRMAOBCYP2A6L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4216713-B2 | — | — | 2009-01-28 | — | — | JP | claimed |
| EP-1404324-A4 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT INC (US) | 2004-12-22 | — | — | EP | claimed |
| JP-2004536873-A | — | — | 2004-12-09 | — | — | JP | claimed |
| EP-1404324-A2 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | Xenoport, Inc. (US) | 2004-04-07 | — | — | EP | claimed |
| US-20030176398-A1 | Prodrugs of GABA analogs, compositions and uses thereof | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2003-09-18 | — | — | US | claimed |
| WO-2002100347-A2 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2002-12-19 | — | — | WO | claimed |
| EP-2085087-A1 | Prodrugs of gaba analogs, compositions and uses thereof | Xenoport, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-1902714-A1 | Prodrugs of gaba analogs, compositions and uses thereof | Xenoport, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176398-A1 | Prodrugs of GABA analogs, compositions and uses thereof | GABRB1, GABRB2, GABRB3 | RELA 4768/4885ALDH1A1 298/4885IDO1 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.